mhurhangee/patent-ind-claim-en huggingface dataset:
A method for establishing a communication between a gateway and a communication module , comprising: • periodically radiobroadcasting in successive radiobroadcasting periods from a gateway a synchronization signal , the synchronization signal being emitted during an emission window exhibiting a defined duration Dx within each radiobroadcasting period, • periodically activating in successive activation periods a receiver of a communication module , the receiver being activated during an awake window within each activation period, the duration of the awake window being less than the duration Tr of the activation period, • receiving the synchronization radio signal by the receiver of the communication module during an overlap between a said awake window and a said emission window , • radiobroadcasting a data message from an emitter of the communication module , the radiobroadcasting of the data message being triggered by the reception of the synchronization signal , • receiving the data message by a receiver of the gateway , characterized in that : • the duty cycle DC=Dx/Tx between the duration of the emission window Dx of the synchronization signal and the duration Tx of the radiobroadcasting period is less than 50%, • the duration Tr of the activation period is equal to Tr=Tx/(1+DC). • periodically radiobroadcasting in successive radiobroadcasting periods from a gateway a synchronization signal , the synchronization signal being emitted during an emission window exhibiting a defined duration Dx within each radiobroadcasting period, • periodically activating in successive activation periods a receiver of a communication module , the receiver being activated during an awake window within each activation period, the duration of the awake window being less than the duration Tr of the activation period, • receiving the synchronization radio signal by the receiver of the communication module during an overlap between a said awake window and a said emission window , • radiobroadcasting a data message from an emitter of the communication module , the radiobroadcasting of the data message being triggered by the reception of the synchronization signal , • receiving the data message by a receiver of the gateway , • the duty cycle DC=Dx/Tx between the duration of the emission window Dx of the synchronization signal and the duration Tx of the radiobroadcasting period is less than 50%, • the duration Tr of the activation period is equal to Tr=Tx/(1+DC).
A configuration method of duplication transmission, comprising: determining each radio bearer of a terminal; and performing a duplication transmission configuration for each radio bearer; characterized in that , the duplication transmission configuration performed for each radio bearer comprises: a Radio Bearer Identity, RB ID, and a configuration of a PDCP entity corresponding to the bearer; two corresponding Logical Channel Identity, LCID, used by the radio bearer for the duplication transmission, and configurations of RLC entities corresponding to the two logical channels respectively; for uplink transmission, configuring initial states of two logical channels as whether to be in an activated state immediately after the configuration; and for uplink transmission, a configuration as to whether to allow to activate or deactivate the duplication transmission. determining each radio bearer of a terminal; and performing a duplication transmission configuration for each radio bearer; characterized in that , the duplication transmission configuration performed for each radio bearer comprises: a Radio Bearer Identity, RB ID, and a configuration of a PDCP entity corresponding to the bearer; two corresponding Logical Channel Identity, LCID, used by the radio bearer for the duplication transmission, and configurations of RLC entities corresponding to the two logical channels respectively; for uplink transmission, configuring initial states of two logical channels as whether to be in an activated state immediately after the configuration; and for uplink transmission, a configuration as to whether to allow to activate or deactivate the duplication transmission. a Radio Bearer Identity, RB ID, and a configuration of a PDCP entity corresponding to the bearer; two corresponding Logical Channel Identity, LCID, used by the radio bearer for the duplication transmission, and configurations of RLC entities corresponding to the two logical channels respectively; for uplink transmission, configuring initial states of two logical channels as whether to be in an activated state immediately after the configuration; and for uplink transmission, a configuration as to whether to allow to activate or deactivate the duplication transmission.
A request processing method, wherein the method is executed by a bare-metal server which comprises a system on chip and a processor , the system on chip communicates with the processor and the method comprises: receiving, by the system on chip , a volume attaching request, wherein the volume attaching request comprises an identifier of a system volume, and the system volume stores a file used for starting an operating system of the bare-metal server ; storing, by the system on chip , the identifier of the system volume based on the volume attaching request; and using, by the processor , the identifier of the system volume to determine the system volume, and starting the operating system of the bare-metal server based on the system volume. receiving, by the system on chip , a volume attaching request, wherein the volume attaching request comprises an identifier of a system volume, and the system volume stores a file used for starting an operating system of the bare-metal server ; storing, by the system on chip , the identifier of the system volume based on the volume attaching request; and using, by the processor , the identifier of the system volume to determine the system volume, and starting the operating system of the bare-metal server based on the system volume.
A device for changing sleeves on cylinder mandrels or adapter sleeves , which can be inserted into a printing press and can removed from it again, comprising: • a safety device at least partially with structurally arranged separating elements and/or with an optically operating safety device, in particular a light or sensor grid, which defines a safety region , wherein the safety region cannot be entered by persons at least during the handling of sleeves , adapter sleeves or cylinder mandrels , • a holding device for temporarily holding a cylinder mandrel or an adapter sleeve , • wherein the holding device is arranged at least partially within the safety region , and wherein the holding device can be arranged or positioned in such a way that the sleeve can be grasped outside the safety region , • wherein a transfer device is arranged within the safety region , by means of which the adapter sleeve and/or the cylinder mandrel can be transported to the holding device . • a safety device at least partially with structurally arranged separating elements and/or with an optically operating safety device, in particular a light or sensor grid, which defines a safety region , wherein the safety region cannot be entered by persons at least during the handling of sleeves , adapter sleeves or cylinder mandrels , • a holding device for temporarily holding a cylinder mandrel or an adapter sleeve , • wherein the holding device is arranged at least partially within the safety region , and wherein the holding device can be arranged or positioned in such a way that the sleeve can be grasped outside the safety region , • wherein a transfer device is arranged within the safety region , by means of which the adapter sleeve and/or the cylinder mandrel can be transported to the holding device .
A composition for use in treating a hyperproliferative disease selected from the group consisting of chronic lymphocytic leukemia, small lymphocytic leukemia, non-Hodgkin's lymphoma, diffuse large B-cell lymphoma, mantle cell lymphoma, follicular lymphoma, B-cell lymphoproliferative disease, B cell acute lymphoblastic leukemia, and Waldenstrom's macroglobulinemia, wherein the composition comprises crystalline ( S )-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5- a ]pyrazin-1-yl)- N -(pyridin-2-yl)benzamide free base wherein the crystalline ( S )-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5- a ]pyrazin-1-yl)- N -(pyridin-2-yl)benzamide free base is characterized by a transmission X-ray powder diffraction pattern comprising peaks at 6.4, 8.6, 10.5, 11.6, and 15.7 °2θ ± 0.2 °2θ, wherein the X-ray powder diffraction pattern was acquired using Cu-K α1 radiation source, and the crystalline ( S )-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5- a ]pyrazin-1-yl)- N -(pyridin-2-yl)benzamide free base is administered at a dose of 100 mg twice daily.
A balloon coating method for forming a coating layer containing a water-insoluble drug on an outer surface of a balloon of a balloon catheter , the method comprising: a step of fitting a drive shaft for rotating the balloon catheter to a proximal portion of a hub of the balloon catheter or an opening portion of an interlocking member to be attached to the proximal portion to fix the drive shaft by using a frictional force; a step of moving a dispensing tube for supplying a coating solution containing the drug relatively to the balloon in a longitudinal axial direction of the balloon while causing the drive shaft to rotate the balloon around an axis (X) of the balloon , so as to apply the coating solution to the outer surface of the balloon , wherein in the application step, while a pulling force is applied to the balloon in the longitudinal axial direction of the balloon , the coating solution containing the drug is applied to the outer surface of the balloon . a step of fitting a drive shaft for rotating the balloon catheter to a proximal portion of a hub of the balloon catheter or an opening portion of an interlocking member to be attached to the proximal portion to fix the drive shaft by using a frictional force; a step of moving a dispensing tube for supplying a coating solution containing the drug relatively to the balloon in a longitudinal axial direction of the balloon while causing the drive shaft to rotate the balloon around an axis (X) of the balloon , so as to apply the coating solution to the outer surface of the balloon , wherein in the application step, while a pulling force is applied to the balloon in the longitudinal axial direction of the balloon , the coating solution containing the drug is applied to the outer surface of the balloon .
An anti-FcRn antibody for use in an in vivo method of detecting FcRn in a subject, the method comprising: administering to the subject the anti-FcRn antibody, and detecting an interaction between the anti-FcRn antibody and FcRn if present, wherein the anti-FcRn antibody comprises a light chain variable region (V L ), and a heavy chain variable region (V H ), wherein the anti-FcRn antibody binds to human FcRn; and wherein the V L comprises: (i) a V L CDR1 comprising the amino acid sequence TGTGSDVGSYNLVS (SEQ ID NO: 14); (ii) a V L CDR2 comprising the amino acid sequence GDSQRPS (SEQ ID NO: 15); and (iii) a V L CDR3 comprising the amino acid sequence SSYAGSGIYV (SEQ ID NO: 12) or ASYAGSGIYV (SEQ ID NO: 13); and the V H comprises: (i) a V H CDR1 comprising the amino acid sequence EYAMG (SEQ ID NO: 22); (ii) a V H CDR2 comprising the amino acid sequence SIGSSGGQTKYADSVKG (SEQ ID NO: 23); and (iii) a V H CDR3 comprising the amino acid sequence LAIGDSY (SEQ ID NO: 24); and wherein the anti-FcRn antibody is conjugated with a detectable molecule. administering to the subject the anti-FcRn antibody, and detecting an interaction between the anti-FcRn antibody and FcRn if present, wherein the anti-FcRn antibody comprises a light chain variable region (V L ), and a heavy chain variable region (V H ), wherein the anti-FcRn antibody binds to human FcRn; and wherein the V L comprises: (i) a V L CDR1 comprising the amino acid sequence TGTGSDVGSYNLVS (SEQ ID NO: 14); (ii) a V L CDR2 comprising the amino acid sequence GDSQRPS (SEQ ID NO: 15); and (iii) a V L CDR3 comprising the amino acid sequence SSYAGSGIYV (SEQ ID NO: 12) or ASYAGSGIYV (SEQ ID NO: 13); and the V H comprises: (i) a V H CDR1 comprising the amino acid sequence EYAMG (SEQ ID NO: 22); (ii) a V H CDR2 comprising the amino acid sequence SIGSSGGQTKYADSVKG (SEQ ID NO: 23); and (iii) a V H CDR3 comprising the amino acid sequence LAIGDSY (SEQ ID NO: 24); and wherein the V L comprises: (i) a V L CDR1 comprising the amino acid sequence TGTGSDVGSYNLVS (SEQ ID NO: 14); (ii) a V L CDR2 comprising the amino acid sequence GDSQRPS (SEQ ID NO: 15); and (iii) a V L CDR3 comprising the amino acid sequence SSYAGSGIYV (SEQ ID NO: 12) or ASYAGSGIYV (SEQ ID NO: 13); (i) a V L CDR1 comprising the amino acid sequence TGTGSDVGSYNLVS (SEQ ID NO: 14); (ii) a V L CDR2 comprising the amino acid sequence GDSQRPS (SEQ ID NO: 15); and (iii) a V L CDR3 comprising the amino acid sequence SSYAGSGIYV (SEQ ID NO: 12) or ASYAGSGIYV (SEQ ID NO: 13); and the V H comprises: (i) a V H CDR1 comprising the amino acid sequence EYAMG (SEQ ID NO: 22); (ii) a V H CDR2 comprising the amino acid sequence SIGSSGGQTKYADSVKG (SEQ ID NO: 23); and (iii) a V H CDR3 comprising the amino acid sequence LAIGDSY (SEQ ID NO: 24); and (i) a V H CDR1 comprising the amino acid sequence EYAMG (SEQ ID NO: 22); (ii) a V H CDR2 comprising the amino acid sequence SIGSSGGQTKYADSVKG (SEQ ID NO: 23); and (iii) a V H CDR3 comprising the amino acid sequence LAIGDSY (SEQ ID NO: 24); and wherein the anti-FcRn antibody is conjugated with a detectable molecule.
A compound of the formula or a pharmaceutically acceptable salt, solvate or stereoisomer thereof, for use in a method of treating or managing Kaposi's sarcoma-associated herpesvirus (KSHV) induced lymphoma, wherein the method comprises: (i) identifying a patient having KSHV-induced lymphoma sensitive to treatment with the compound; wherein said identifying comprises measuring a level of major histocompatibility complex class I (MHC-1) in a biological sample obtained from the patient, wherein a decreased level of MHC-1 relative to a control sample indicates a likelihood that the patient is sensitive to treatment with the compound; and (ii) administering to the patient a therapeutically effective amount of the compound in a 28 day cycle comprising 21 consecutive days of administration followed by seven consecutive days of rest. (i) identifying a patient having KSHV-induced lymphoma sensitive to treatment with the compound; wherein said identifying comprises measuring a level of major histocompatibility complex class I (MHC-1) in a biological sample obtained from the patient, wherein a decreased level of MHC-1 relative to a control sample indicates a likelihood that the patient is sensitive to treatment with the compound; and (ii) administering to the patient a therapeutically effective amount of the compound in a 28 day cycle comprising 21 consecutive days of administration followed by seven consecutive days of rest.
An electronic device , comprising; a drift layer having a first conductivity type, and including a first portion and a second portion; a buffer layer on the drift layer and having a second conductivity type, and including a third portion and a fourth portion, wherein the buffer layer forms a first mesa that is on the first portion of the drift layer and forms a P-N junction with the drift layer, and wherein the buffer layer is not on the second portion of the drift layer and wherein the buffer layer includes an upper corner that is spaced apart vertically from the drift layer by the buffer layer; a second layer on the buffer layer opposite the drift layer and having the second conductivity type, wherein the second layer forms a second mesa that is on the third portion of the buffer layer and that is not on the fourth portion of the buffer layer adjacent the second portion of the drift layer and wherein the second layer includes a lower corner in contact with the buffer layer, that is spaced apart horizontally from the upper corner of the buffer layer by a distance W and that is spaced apart vertically from the drift layer by the buffer layer, wherein the second mesa includes a vertical sidewall that is spaced apart horizontally from the upper corner of the buffer layer; a junction termination region in the second portion of the drift layer, wherein the junction termination region has the second conductivity type; the electronic device being characterized in a buried junction extension in the first portion of the drift layer that has the second conductivity type, that is in direct contact with the buffer layer and the junction termination region, and that is beneath the fourth portion of the buffer layer, wherein a first side of the buried junction extension is vertically aligned with a sidewall of the first mesa and a second side of the buried junction extension opposite the junction termination region is vertically aligned with the vertical sidewall of the second mesa .
A medical device , comprising: an end effector (100, 100', 100") at a distal end of the medical device; an actuator coupled to a proximal end of the end effector (100, 100', 100"); a pivot arm pivotally coupled to the end effector (100, 100', 100") distal of the proximal end of the end effector (100, 100', 100"), wherein actuation of the actuator pivots the end effector relative to the pivot arm; characterized in that the medical device further comprises: a lock on the end effector and the pivot arm , wherein the lock has a first state permitting the end effector (100, 100', 100") to pivot relative to the pivot arm and a second state restricting the end effector (100, 100', 100") from pivoting relative to the pivot arm . an end effector (100, 100', 100") at a distal end of the medical device; an actuator coupled to a proximal end of the end effector (100, 100', 100"); a pivot arm pivotally coupled to the end effector (100, 100', 100") distal of the proximal end of the end effector (100, 100', 100"), wherein actuation of the actuator pivots the end effector relative to the pivot arm; characterized in that the medical device further comprises: a lock on the end effector and the pivot arm , wherein the lock has a first state permitting the end effector (100, 100', 100") to pivot relative to the pivot arm and a second state restricting the end effector (100, 100', 100") from pivoting relative to the pivot arm .
A system enhanced for the simplification of the packaging process of the products by the cashier, customer or personnel in the markets, supermarkets and similar places, providing the automatic packaging of the products, characterized in that it comprises: • reels providing the products read by the barcode reader and sent from the cash point to move towards the packaging part. • product guider palette providing the products coming through the reels to move towards the product flow channel . • product flow channel preventing the products to overflow into the exiting part of the packaging section , having at least one bag stopper (4.1) in the head part. • packaging section including the solenoid valve (5.1) operating with the information coming from the cash point and at least one bag holder connecting tab performing the process of pulling out of the bag to be stored inside the products from the bag roller and of leaving from the system when the bag is in a certain weight. • product slideway where the bag full of products leaves the system. • bag roller including the bags where the products will be put. • carrier body carrying the whole system. • reels providing the products read by the barcode reader and sent from the cash point to move towards the packaging part. • product guider palette providing the products coming through the reels to move towards the product flow channel . • product flow channel preventing the products to overflow into the exiting part of the packaging section , having at least one bag stopper (4.1) in the head part. • packaging section including the solenoid valve (5.1) operating with the information coming from the cash point and at least one bag holder connecting tab performing the process of pulling out of the bag to be stored inside the products from the bag roller and of leaving from the system when the bag is in a certain weight. • product slideway where the bag full of products leaves the system. • bag roller including the bags where the products will be put. • carrier body carrying the whole system.
An electrochemical cell comprising: a positive current collector , in which an injection part , an ejection part and a passage are defined, wherein air including oxygen is injected through the injection part , an exhaust gas is ejected through the ejection part , and the passage defines a single path having a meandering shape, which connects the injection part and the ejection part ; and a unit cell disposed to be adjacent to the positive current collector , wherein the unit cell comprises: a positive electrode layer adjacent to the positive current collector , wherein the oxygen is an active material thereof; a negative electrode metal layer disposed opposite to the positive current collector with respect to the positive electrode layer ; and an electrolyte membrane interposed between the positive electrode layer and the negative electrode metal layer , wherein the positive electrode layer contacts a surface of the positive current collector , characterised in that at least a part of the passage is opened toward a surface of the positive electrode layer , and in that the positive electrode layer is positioned immediately next to the passage . a positive current collector , in which an injection part , an ejection part and a passage are defined, wherein air including oxygen is injected through the injection part , an exhaust gas is ejected through the ejection part , and the passage defines a single path having a meandering shape, which connects the injection part and the ejection part ; and a unit cell disposed to be adjacent to the positive current collector , wherein the unit cell comprises: a positive electrode layer adjacent to the positive current collector , wherein the oxygen is an active material thereof; a negative electrode metal layer disposed opposite to the positive current collector with respect to the positive electrode layer ; and an electrolyte membrane interposed between the positive electrode layer and the negative electrode metal layer , a positive electrode layer adjacent to the positive current collector , wherein the oxygen is an active material thereof; a negative electrode metal layer disposed opposite to the positive current collector with respect to the positive electrode layer ; and an electrolyte membrane interposed between the positive electrode layer and the negative electrode metal layer , wherein the positive electrode layer contacts a surface of the positive current collector , characterised in that at least a part of the passage is opened toward a surface of the positive electrode layer , and in that the positive electrode layer is positioned immediately next to the passage .